AB 2180: Health care coverage: cost sharing.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-04-30
Current Status:
Failed
(2024-05-16: In committee: Held under submission.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law generally prohibits a person who manufactures a prescription drug from offering in California any discount, repayment, product voucher, or other reduction in an individuals out-of-pocket expenses associated with the individuals health insurance, health care service plan, or other health coverage, including, but not limited to, a copayment, coinsurance, or deductible, for any prescription drug if a lower cost generic drug is covered under the individuals health insurance, health care service plan, or other health coverage on a lower cost-sharing tier that is designated as therapeutically equivalent to the prescription drug manufactured by that person or if the active ingredients of the drug are contained in products regulated by the federal Food and Drug Administration, are available without prescription at a lower cost, and are not otherwise contraindicated for the condition for which the prescription drug is approved.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require a health care service plan, health insurance policy, or pharmacy benefit manager that administers pharmacy benefits for a health care service plan or health insurer to apply any amounts paid by the enrollee, insured, or a third-party patient assistance program, as defined, program for prescription drugs toward the enrollees or insureds cost-sharing requirement, and would only apply those requirements with respect to enrollees or insureds who have a chronic disease or terminal illness. The bill would limit the application of the section to health care service plans and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2025. Because a willful violation of these requirements by a health care service plan would be a crime, this bill would impose a state-mandated local program. The bill would repeal those provisions on January 1, 2035. The bill would require the Department of Managed Health Care and the Department of Insurance, by March 31, 2034, to provide a report to the appropriate policy committees of the Legislature on the impact of the provisions on drug prices and health care premium rates, including a recommendation whether the repeal date should be deleted.
Existing law requires a health care service plan or health insurer that files certain rate information to report to the appropriate department specified cost information regarding covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs, dispensed as provided.
This bill, until January 1, 2035, additionally would require health care service plans and health insurers to report the 25 most frequently prescribed drugs with a patient assistance program, as described in the bill, and the 25 most costly drugs, by total annual plan spending, with a prescription assistance program, as described in the bill. The bill also would require the health care service plan or health insurer to report the aggregate dollar amount of all patient assistance programs that the health care service plan, health insurer, or their designee collected from all third-party entities in connection with the bills cost-sharing requirements that are attributable to drug utilization by enrollees or insureds during that calendar year.
Because a willful violation of the bills requirements by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law generally prohibits a person who manufactures a prescription drug from offering in California any discount, repayment, product voucher, or other reduction in an individuals out-of-pocket expenses associated with the individuals health insurance, health care service plan, or other health coverage, including, but not limited to, a copayment, coinsurance, or deductible, for any prescription drug if a lower cost generic drug is covered under the individuals health insurance, health care service plan, or other health coverage on a lower cost-sharing tier that is designated as therapeutically equivalent to the prescription drug manufactured by that person or if the active ingredients of the drug are contained in products regulated by the federal Food and Drug Administration, are available without prescription at a lower cost, and are not otherwise contraindicated for the condition for which the prescription drug is approved.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require a health care service plan, health insurance policy, or pharmacy benefit manager that administers pharmacy benefits for a health care service plan or health insurer to apply any amounts paid by the enrollee, insured, or another source pursuant to a discount, repayment, product voucher, or other reduction to the enrollees or insureds out-of-pocket expenses a third-party patient assistance program, as defined, toward the enrollees or insureds overall contribution to any out-of-pocket maximum, deductible, copayment, coinsurance, or applicable cost-sharing requirement under the enrollees or insureds health care service plan contract or health insurance policy. cost-sharing requirement, and would only apply those requirements with respect to enrollees or insureds who have a chronic disease or terminal illness. The bill would limit the application of the section to health care service plans and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2025. Because a willful violation of these requirements by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law generally prohibits a person who manufactures a prescription drug from offering in California any discount, repayment, product voucher, or other reduction in an individuals out-of-pocket expenses associated with the individuals health insurance, health care service plan, or other health coverage, including, but not limited to, a copayment, coinsurance, or deductible, for any prescription drug if a lower cost generic drug is covered under the individuals health insurance, health care service plan, or other health coverage on a lower cost-sharing tier that is designated as therapeutically equivalent to the prescription drug manufactured by that person or if the active ingredients of the drug are contained in products regulated by the federal Food and Drug Administration, are available without prescription at a lower cost, and are not otherwise contraindicated for the condition for which the prescription drug is approved.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require a health care service plan, health insurance policy, or pharmacy benefit manager that administers pharmacy benefits for a health care service plan or health insurer to apply any amounts paid by the enrollee, insured, or another source pursuant to a discount, repayment, product voucher, or other reduction to the enrollees or insureds out-of-pocket expenses toward the enrollees or insureds overall contribution to any out-of-pocket maximum, deductible, copayment, coinsurance, or applicable cost-sharing requirement under the enrollees or insureds health care service plan contract or health insurance policy. The bill would limit the application of the section to health care service plans and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2025. Because a willful violation of these requirements by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)(1)To the extent permitted by federal law, and consistent with Sections 132000 and 132002, a health care service plan or a pharmacy benefit manager that administers pharmacy benefits for a health care service plan shall apply any amounts paid by either the enrollee or third-party patient assistance program for prescription drugs to the enrollees cost-sharing requirement. This requirement shall be limited to only those enrollees who have a chronic disease or terminal illness.
(2)When calculating an enrollees overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health care service plan shall include expenditures for any item or service covered by the health care service plan, and include within a category of essential health benefits, as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health care service plan contract.
(3)This section shall only apply with respect to health care service plan contracts issued, amended, delivered, or renewed on or after January 1, 2025.
(b)If under federal law, application of subdivision (a) would result in health savings account ineligibility under Section 223 of the Internal Revenue Code, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of a policy after the enrollee has satisfied the minimum deductible under Section 223 of the Internal Revenue Code, except with respect to items or services that are preventive care pursuant to Section 223(c)(2)(C) of the Internal Revenue Code, in which case the requirements of this subdivision shall apply regardless of whether the minimum deductible under Section 223 of the Internal Revenue Code has been satisfied.
(c)This section does not apply with respect to self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Public Law 83-406).
(d)For purposes of this section, the following definitions apply:
(1)Cost-sharing requirement means any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, required by, or on behalf of, an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health care service plan contract.
(2)Pharmacy benefit manager means a person or business that administers the prescription drug or device program of one or more health care service plans on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.
(3)Third-party patient assistance program shall include, but is not limited to, manufacturer or charitable cost-sharing or copay assistance programs that provide financial assistance intended to assist patients in paying their out-of-pocket cost-sharing obligations for prescription drugs. Third-party patient assistance program does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug.
(4)Chronic disease is defined as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both.
(5)Terminal illness is defined as a medical condition that is life-limiting life limiting and expected to result in death.
(e)(1)On or before March 31, 2034, the department shall provide a report to the appropriate policy committees of the Legislature on the impact of this section on drug prices and health care premium rates, and to include the departments recommendation whether the repeal date in subdivision (f) should be deleted.
(2)A report provided pursuant to paragraph (1) shall be submitted in compliance with Section 9795 of the Government Code.
(f)This section shall remain in effect only until January 1, 2035, and as of that date is repealed.
SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)(A)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)(i)The 25 most frequently prescribed drugs.
(B)(ii)The 25 most costly drugs by total annual plan spending.
(C)(iii)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(iv)The 25 most frequently prescribed drugs with a patient assistance program pursuant to Section 1367.0062.
(v)The 25 most costly drugs by total annual plan spending with a prescription assistance program pursuant to Section 1367.0062.
(B)For each plan with a prescription drug benefit that the health care service plan issued for delivery, renewed, amended, or continued during the immediately preceding calendar year, the aggregate dollar amount of all patient assistance programs that the health care service plan or a designee of the health care service plan collected, directly or indirectly, from all third-party entities in connection with Section 1367.002 that are attributable to enrollee drug utilization during that calendar year shall be reported.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. and third-party patient assistance programs on health care premiums, cost sharing, and payments to pharmacy benefit managers. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its Internet Web site internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(g)This section shall remain in effect only until January 1, 2035, and as of that date is repealed.
SEC. 3.Section 1367.243 is added to the Health and Safety Code, to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(g)This section shall become operative on January 1, 2035.
SEC. 4.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)(A)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)(i)The 25 most frequently prescribed drugs.
(B)(ii)The 25 most costly drugs by total annual plan spending.
(C)(iii)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(iv)The 25 most frequently prescribed drugs with a patient assistance program pursuant to Section 10192.292.
(v)The 25 most costly drugs by total annual plan spending with a prescription assistance program pursuant to Section 10192.292.
(B)For each plan with a prescription drug benefit that the health insurer issued for delivery, renewed, amended, or continued during the immediately preceding calendar year, the aggregate dollar amount of all patient assistance programs that the health insurer or a designee of the health insurer collected, directly or indirectly, from all third-party entities in connection with Section 10192.292 that are attributable to drug utilization by insureds during that calendar year shall be reported.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. and third-party patient assistance programs on health care premiums, cost sharing, and payments to pharmacy benefit managers. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its Internet Web site internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(g)This section shall remain in effect only until January 1, 2035, and as of that date is repealed.
SEC. 5.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
(g)This section shall become operative on January 1, 2035.
SEC. 2.SEC. 6.Section 10192.292 is added to the Insurance Code, to read:10192.292.(a)(1)To the extent permitted by federal law, and consistent with Sections 132000 and 132002 of the Health and Safety Code, a health insurer or a pharmacy benefit manager that administers pharmacy benefits for a health insurer shall apply any amounts paid by either the insured, or third-party patient assistance program for prescription drugs to the insureds cost-sharing requirement. This requirement shall be limited to only those insureds who have a chronic disease or terminal illness.
(2)When calculating an insureds overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health insurer shall include expenditures for any item or service covered by the health insurer, and include within a category of essential health benefits, as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health insurance policy.
(3)This section shall only apply with respect to health insurance policies issued, amended, delivered, or renewed on or after January 1, 2025.
(b)If under federal law, application of subdivision (a) would result in health savings account ineligibility under Section 223 of the Internal Revenue Code, this requirement shall apply for Health Savings Account-qualified High Deductible Health Plans with respect to the deductible of a policy after the insured has satisfied the minimum deductible under Section 223 of the Internal Revenue Code, except with respect to items or services that are preventive care pursuant to Section 223(c)(2)(C) of the Internal Revenue Code, in which case the requirements of this subdivision shall apply regardless of whether the minimum deductible under Section 223 of the Internal Revenue Code has been satisfied.
(c)This section does not apply with respect to self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Public Law 83-406).
(d)For purposes of this section, the following definitions apply:
(1)Cost-sharing requirement means any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, required by, or on behalf of, an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health insurance policy.
(2)Pharmacy benefit manager means a person or business that administers the prescription drug or device program of one or more health insurance policies on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.
(3)Third-party patient assistance program shall include, but is not limited to, manufacturer or charitable cost-sharing or copay assistance programs that provide financial assistance intended to assist patients in paying their out-of-pocket cost-sharing obligations for prescription drugs. Third-party patient assistant program does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug.
(4)Chronic disease is defined as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both.
(5)Terminal illness is defined as a medical condition that is life-limiting life limiting and expected to result in death.
(e)(1)On or before March 31, 2034, the department shall provide a report to the appropriate policy committees of the Legislature on the impact of this section on drug prices and health care premium rates, and to include the departments recommendation whether the repeal date in subdivision (f) should be deleted.
(2)A report provided pursuant to paragraph (1) shall be submitted in compliance with Section 9795 of the Government Code.
(f)This section shall remain in effect only until January 1, 2035, and as of that date is repealed.
SEC. 3.SEC. 7.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)To the extent permitted by federal law, and consistent with Sections 132000 and 132002, a health care service plan or a pharmacy benefit manager that administers pharmacy benefits for a health care service plan shall apply any amounts paid by either the enrollee or third-party patient assistance program to the enrollees cost-sharing requirement. This requirement shall be limited to only those enrollees who have a chronic disease or terminal illness.
(2)When calculating an enrollees overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health care service plan shall include expenditures for any item or service covered by the health care service plan, and include within a category of essential health benefits, as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health care service plan contract.
(2)(3)This section shall only apply with respect to health care service plan contracts issued, amended, delivered, or renewed on or after January 1, 2025.
(b)If under federal law, application of subdivision (a) would result in health savings account ineligibility under Section 223 of the Internal Revenue Code, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of a policy after the enrollee has satisfied the minimum deductible under Section 223 of the Internal Revenue Code, except with respect to items or services that are preventive care pursuant to Section 223(c)(2)(C) of the Internal Revenue Code, in which case the requirements of this subdivision shall apply regardless of whether the minimum deductible under Section 223 of the Internal Revenue Code has been satisfied.
(c)This section does not apply with respect to self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Public Law 83-406).
(d)For purposes of this section, the following definitions apply:
(1)Cost-sharing requirement means any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, required by, or on behalf of, an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health care service plan contract. When calculating an enrollees overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health care service plan shall include expenditures for any item or service covered by the health care service plan, and include within a category of essential health benefits as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health care service plan contract.
(2)Pharmacy Benefit Manager benefit manager means a person or business that administers the prescription drug or device program of one or more health care service plans on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.
(3)Third-party patient assistance program shall include, but is not limited to, manufacturer or other charitable cost-sharing or copay assistance programs that provide financial assistance intended to augment existing prescription drug coverage. Third-party patient assistance program does not include discounts, drug vouchers, or general manufacturer coupons. assist patients in paying their out-of-pocket cost-sharing obligations for prescription drugs. Third-party patient assistance program does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug.
(4)Chronic disease is defined as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both.
(5)Terminal illness is defined as a medical condition that is life-limiting and expected to result in death.
SEC. 2.Section 10192.292 is added to the Insurance Code, to read:10192.292.(a)(1)To the extent permitted by federal law, and consistent with Sections 132000 and 132002 of the Health and Safety Code, a health insurer or a pharmacy benefit manager that administers pharmacy benefits for a health insurer shall apply any amounts paid by either the insured, or third-party patient assistance program to the insureds cost-sharing requirement. This requirement shall be limited to only those insureds who have a chronic disease or terminal illness.
(2)When calculating an insureds overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health insurer shall include expenditures for any item or service covered by the health insurer, and include within a category of essential health benefits, as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health insurance policy.
(2)(3)This section shall only apply with respect to health insurance policies issued, amended, delivered, or renewed on or after January 1, 2025.
(b)If under federal law, application of subdivision (a) would result in health savings account ineligibility under Section 223 of the Internal Revenue Code, this requirement shall apply for Health Savings Account-qualified High Deductible Health Plans with respect to the deductible of a policy after the insured has satisfied the minimum deductible under Section 223 of the Internal Revenue Code, except with respect to items or services that are preventive care pursuant to Section 223(c)(2)(C) of the Internal Revenue Code, in which case the requirements of this subdivision shall apply regardless of whether the minimum deductible under Section 223 of the Internal Revenue Code has been satisfied.
(c)This section does not apply with respect to self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Public Law 83-406).
(d)For purposes of this section, the following definitions apply:
(1)Cost-sharing requirement means any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, required by, or on behalf of, an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health insurance policy. When calculating an insureds overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health insurer shall include expenditures for any item or service covered by the health insurer, and include within a category of essential health benefits as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health insurance policy.
(2)Pharmacy Benefit Manager benefit manager means a person or business that administers the prescription drug or device program of one or more health insurance policies on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.
(3)Third-party patient assistance program shall include, but is not limited to, manufacturer or other charitable cost-sharing or copay assistance programs that provide financial assistance intended to augment existing prescription drug coverage. Third party patient assistance program does not include discounts, drug vouchers or general manufacturer coupons. assist patients in paying their out-of-pocket cost-sharing obligations for prescription drugs. Third-party patient assistant program does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug.
(4)Chronic disease is defined as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both.
(5)Terminal illness is defined as a medical condition that is life-limiting and expected to result in death.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)To the extent permitted by federal law, and consistent with Sections 132000 and 132002, a health care service plan or a pharmacy benefit manager that administers pharmacy benefits for a health care service plan shall apply any amounts paid by either the enrollee or third-party patient assistance program to the enrollees cost-sharing requirement. This requirement shall be limited to only those enrollees who have a chronic disease or terminal illness.
(2)This section shall only apply with respect to health care service plan contracts issued, amended, delivered, or renewed on or after January 1, 2025.
(b)If under federal law, application of subdivision (a) would result in health savings account ineligibility under Section 223 of the Internal Revenue Code, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of a policy after the enrollee has satisfied the minimum deductible under Section 223 of the Internal Revenue Code, except with respect to items or services that are preventive care pursuant to Section 223(c)(2)(C) of the Internal Revenue Code, in which case the requirements of this subdivision shall apply regardless of whether the minimum deductible under Section 223 of the Internal Revenue Code has been satisfied.
(c)This section does not apply with respect to self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Public Law 83-406).
(d)For purposes of this section, the following definitions apply:
(1)Cost-sharing requirement means any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, required by, or on behalf of, an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health care service plan contract. When calculating an enrollees overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health care service plan shall include expenditures for any item or service covered by the health care service plan, and include within a category of essential health benefits as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health care service plan contract.
(2)Pharmacy Benefit Manager means a person or business that administers the prescription drug or device program of one or more health care service plans on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.
(3)Third-party patient assistance program shall include, but is not limited to, manufacturer or other charitable programs that provide financial assistance intended to augment existing prescription drug coverage. Third-party patient assistance program does not include discounts, drug vouchers, or general manufacturer coupons.
(4)Chronic disease is defined as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both.
(5)Terminal illness is defined as a medical condition that is life-limiting and expected to result in death.
SEC. 2.Section 10192.292 is added to the Insurance Code, to read:10192.292.(a)(1)To the extent permitted by federal law, and consistent with Sections 132000 and 132002 of the Health and Safety Code, a health insurer or a pharmacy benefit manager that administers pharmacy benefits for a health insurer shall apply any amounts paid by either the insured, or third-party patient assistance program to the insureds cost-sharing requirement. This requirement shall be limited to only those insureds who have a chronic disease or terminal illness.
(2)This section shall only apply with respect to health insurance policies issued, amended, delivered, or renewed on or after January 1, 2025.
(b)If under federal law, application of subdivision (a) would result in health savings account ineligibility under Section 223 of the Internal Revenue Code, this requirement shall apply for Health Savings Account-qualified High Deductible Health Plans with respect to the deductible of a policy after the insured has satisfied the minimum deductible under Section 223 of the Internal Revenue Code, except with respect to items or services that are preventive care pursuant to Section 223(c)(2)(C) of the Internal Revenue Code, in which case the requirements of this subdivision shall apply regardless of whether the minimum deductible under Section 223 of the Internal Revenue Code has been satisfied.
(c)This section does not apply with respect to self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Public Law 83-406).
(d)For purposes of this section, the following definitions apply:
(1)Cost-sharing requirement means any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, required by, or on behalf of, an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health insurance policy. When calculating an insureds overall contribution to the annual limitation on cost sharing set forth in Sections 18022(c) and 300gg-6(b) of Title 42 of the United States Code, a health insurer shall include expenditures for any item or service covered by the health insurer, and include within a category of essential health benefits as described in Section 18022(b)(1) of Title 42 of the United States Code, which expenditures shall be considered expenditures for essential health coverage benefits covered under the health insurance policy.
(2)Pharmacy Benefit Manager means a person or business that administers the prescription drug or device program of one or more health insurance policies on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.
(3)Third-party patient assistance program shall include, but is not limited to, manufacturer or other charitable programs that provide financial assistance intended to augment existing prescription drug coverage. Third party patient assistance program does not include discounts, drug vouchers or general manufacturer coupons.
(4)Chronic disease is defined as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both.
(5)Terminal illness is defined as a medical condition that is life-limiting and expected to result in death.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| May 16, 2024 | In committee: Held under submission. |
| May 16, 2024 | Joint Rule 62(a), file notice suspended. (Page 5215.) |
| May 15, 2024 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| May 1, 2024 | Re-referred to Com. on APPR. |
| Apr 30, 2024 | Read second time and amended. |
| Apr 29, 2024 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 23). |
| Apr 11, 2024 | Re-referred to Com. on HEALTH. |
| Apr 10, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Feb 26, 2024 | Referred to Com. on HEALTH. |
| Feb 8, 2024 | From printer. May be heard in committee March 9. |
| Feb 7, 2024 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 23, 2024 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Aids Healthcare Foundation | ** Support | |
| AIM at Melanoma Foundation | ** Support | |
| Aimed Alliance | ** Support | |
| Alliance for Gout Awareness | ** Support | |
| Alliance for Patient Access | ** Support | |
| ALS Association | ** Support | |
| American Cancer Society Cancer Action Network Inc. | ** Support | |
| American Diabetes Association | ** Support | |
| America'S Health Insurance Plans | ** Against | |
| Arthritis Foundation | ** Support | |
| Association for Clinical Oncology | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Association Of Northern California Oncologists | ** Support | |
| Association of Women in Rheumatology | ** Support | |
| California Academy of Physician Assistants | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Black Health Network | ** Support | |
| California Chamber Of Commerce | ** Against | |
| California Chapter American College Of Cardiology | ** Support | |
| California Chronic Care Coalition | ** Support | |
| California Life Sciences | ** Support | |
| California Medical Association | ** Support | |
| California Pharmacists Association | ** Support | |
| California Retired Teachers Association | ** Support | |
| California Rheumatology Alliance | ** Support | |
| California Society Of Dermatology & Dermatologic Surgery | ** Support | |
| California Society Of Plastic Surgeons | ** Support | |
| California Urological Association | ** Support | |
| Cancer Support Community San Francisco Bay Area | ** Support | |
| Center for Inherited Blood Disorders | ** Support | |
| Central California Hemophilia Foundation | ** Support | |
| Children'S Hospital Los Angeles | ** Support | |
| Children'S Specialty Care Coalition | ** Support | |
| Chronic Care Policy Alliance | ** Support | |
| Chronic Disease Coalition | ** Support | |
| community oncology alliance | ** Support | |
| Crohns And Colitis Foundation | ** Support | |
| Cystic Fibrosis Foundation | ** Support | |
| Cystic Fibrosis Research Institute | ** Support | |
| Everylife Foundation For Rare Diseases | ** Support | |
| Global Healthy Living Foundation | ** Support | |
| Hemophilia Council Of California | ** Support | |
| hemophilia federation of america | ** Support | |
| Hemophilia Foundation of Northern California | ** Support | |
| Hemophilia Foundation of Southern California | ** Support | |
| HIV + Hepatitis Policy Institute | ** Support | |
| ICAN, International Cancer Advocacy Network | ** Support | |
| Infusion Access Foundation | ** Support | |
| International Foundation for Autoimmune and Inflammatory Arthritis | ** Support | |
| Looms for Lupus | ** Support | |
| Lung Cancer Foundation of America | ** Support | |
| Lungevity Foundation | ** Support | |
| Lupus and Allied Diseases Association, INC. | ** Support | |
| Medical Oncology Association Of Southern California | ** Support | |
| Movement Disorders Policy Coalition | ** Support | |
| National Bleeding Disorders Foundation | ** Support | |
| National Health Law Program | ** Support | |
| National Infusion Center Association | ** Support | |
| National Multiple Sclerosis Society, Mscan | ** Support | |
| National Psoriasis Foundation | ** Support | |
| Oncology Nursing Society | ** Support | |
| Osteopathic Physicians And Surgeons Of California | ** Support | |
| Pharmaceutical Care Management Association | ** Against | |
| Rady Children's Hospital San Diego | ** Support | |
| Sickle Cell Disease Foundation | ** Support | |
| Spondylitis Association of America | ** Support | |
| Support Fibromyalgia Network | ** Support | |
| The AIDS Institute | ** Support | |
| The Defeating Epilepsy Foundation | ** Support | |
| The Hemophilia Association of San Diego County | ** Support | |
| UCSF Adult Hemophilia Treatment Center | ** Support | |
| Vision Health Advocacy Coalition | ** Support | |
| We Win Foundation | ** Support |
Date of Hearing: April 23, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 2180
Author:((Weber) – As Amended Ver:April 10, 2024
SUBJECT: Health care coverage: cost sharing.
SUMMARY: Requires a health plan, insurer, or pharmacy benefit manager (PBM) to apply any amounts paid by the enrollee, insured, or third party patient assistance program (PAP) towards the enrollee or insured’s cost sharing requirement for those who have a chronic disease or terminal illness. Specifically, this bill:
- Requires a health plan, insurer, or PBM that administers pharmacy benefits for a health plan or insurer to apply any amounts paid by either the enrollee or insured or PAP to the enrollee or insured’s cost sharing requirement, to the extent permitted by federal law, and consistent with existing law relating to prescription drug discount prohibitions. Limits requirements to only those enrollees or insureds who have a chronic disease or terminal illness.
- Requires a health plan or insurer to include expenditures for any item or service covered by the health plan or insurer, and include within a category of essential health benefits (EHBs) when calculating an enrollee or insured’s overall contribution to the annual limitation on cost sharing set forth in existing federal law.
- Specifies that if under federal law, 1) above would result in health savings account (HSA) ineligibility, this requirement to apply for HSA-qualified high deductible health plans (HDHP) with respect to the deductible of a policy after the enrollee or insured has satisfied the minimum deductible under federal law, except with respect to items or services that are preventive care, as specified.
- Exempts provisions of this bill from self-insured employer plans governed by the Employee Retirement Income Security Act of 1974.
- Defines the following:
- Cost-sharing requirement as any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to federal law, required by, or on behalf of, an enrollee or insured in order to receive a specific health care service, including a prescription drug, covered by a health plan contract or insurance policy;
- PBM as a person or business that administers the prescription drug or device program of one or more health plans or insurers on behalf of a third party in accordance with a pharmacy benefit program. Includes any agent or representative of a PBM hired or contracted by the PBM to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a PBM;
- PAP to include, but is not limited to, manufacturer or charitable cost-sharing or copay assistance programs that provide financial assistance intended to assist patients in paying their out-of-pocket (OOP) cost-sharing obligations for prescription drugs. Third-party PAP does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug;
- Chronic disease as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both; and,
- Terminal illness as a medical condition that is life-limiting and expected to result in death.
EXISTING LAW:
- Establishes DMHC to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) §1340, et seq., and Insurance Code (INS) §106, et seq.]
- Establishes as California's EHB benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and 10 Patient Protection and Affordable Care Act mandated benefits, including prescription drugs. [HSC §1367.005 and INS §10112.27]
- Prohibits, with respect to an individual or group health plan contract or health insurance policy that covers EHBs, the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription for a supply of up to 30 days from exceeding $250; for a product with an actuarial value at or equivalent to a Bronze level, limits cost sharing to not more than $500 for a supply of up to 30 days; and for a HDHP the $250 or $500 limits apply only after an enrollee’s deductible is met. [HSC §1342.73 and INS §10123.1932]
- Requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums. [HSC §1356.243 and INS §10123.205]
- Requires health plans and insurers, for all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, to report:
- The 25 most frequently prescribed drugs;
- The 25 most costly drugs by total annual plan spending; and,
- The 25 drugs with the highest year-over-year increase in total annual plan spending. [HSC §1356.243 and INS §10123.205]
- Requires DMHC and CDI to compile the information from 5) above into a report for the public and Legislators where the data is aggregated and does not reveal information specific to individual plans. Requires the report to be published on DMHC’s and CDI’s website. [HSC §1356.243 and INS §10123.205]
- Defines a PBM as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs. [HSC §1385.001]
- Requires a health plan that contracts with a PBM to require the PBM to comply with specified requirements including register with DMHC and exercise good faith and fair dealing in the performance of its duties. [HSC §1385.004 and §1385.005]
- Requires the failure by a health plan to comply with PBM contractual requirements to constitute grounds for disciplinary action. Requires the DMHC Director, as appropriate, to investigate and take enforcement action against a health plan that fails to comply with these requirements and to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. [HSC §1385.006]
- Prohibits a person who manufactures a prescription drug from offering in the state a discount, repayment, product voucher, or other reduction in an individual’s OOP expenses associated with his or her health insurance, health plan, or other health coverage, including, but not limited to, a copayment, coinsurance, or deductible, for a prescription drug if a lower cost generic drug is covered under the individual’s health insurance, health plan, or other health coverage on a lower cost-sharing tier that is designated to be therapeutically equivalent as indicated by the United States Food and Drug Administration’s (FDA) “Approved Drug Products with Therapeutic Equivalence Evaluations.” [HSC §132000]
- Exempts from 9) above, the a single-tablet drug regimen for treatment or prevention of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) that is as effective as a multitablet regimen, unless, consistent with clinical guidelines and peer-reviewed scientific and medical literature, the multitablet regimen is clinically equally effective or more effective and is more likely to result in adherence to the drug regimen; and, an individual who has completed any applicable step therapy or prior authorization requirements for the branded prescription drug as mandated by the individual’s health insurer, health plan, or other health coverage from the prohibition in 9) above. [HSC §132004]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill will have California join 16 other states and Puerto Rico in banning the copay accumulator programs. These programs are used by health insurers and PBMs to prevent copay assistance given to patients from counting towards their deductible and maximum OOP spending. This practice reduces the cost to payers while placing an extreme financial burden on patients, who then are forced to pay OOP to reach their full deductibles or forego their life-saving medications because they can’t afford it. Copay assistance is provided by drug manufacturers, charitable foundations and other third parties to help patients pay for their prescriptions, sometimes saving them thousands of dollars. However, health plans and PBMs are keeping the value of the copay assistance, turning the help given to patients into more profit for themselves. The author concludes that this bill would ban the practice of copay accumulator programs to lift the burden from patients
- BACKGROUND.
- Prescription Drug Spending and SB 17 DMHC Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The DMHC considers the total volume of prescription drugs prescribed by health plans and the total cost paid by health plans for these drugs, on both an aggregate spending level and a per member per month basis and compares the annualized data. The DMHC also analyzes how the 25 most frequently prescribed drugs, the 25 most costly drugs, and the 25 drugs with the highest year-over-year increase in total annual spending impacted health plan premiums over the course of the last four years. The most recent report notes the following key findings:
- Health plans paid about $12.1 billion for prescription drugs in 2022, an increase of almost $1.3 billion, or 12.3%, from 2021. Since 2017, prescription drug costs paid by health plans increased by $3.4 billion or 39%;
- Prescription drugs accounted for 14.2% of total health plan premiums in 2022, an increase from 13.3% in 2021;
- Total prescription drug costs increased by 12.3% in 2022, whereas total medical expenses increased by 7.9%. Overall, total health plan premiums increased by 4.4% from 2021 to 2022;
- Manufacturer drug rebates totaled approximately $2.068 billion, up from $1.674 billion in 2021 and $1.437 billion in 2020. This represents about 17.1% of the $12.1 billion spent on prescription drugs in 2022;
- While specialty drugs accounted for only 1.6% of all prescription drugs dispensed, they accounted for 64% of total annual spending on prescription drugs;
- Generic drugs accounted for 88.9% of all prescribed drugs but only 14.4% of the total annual spending on prescription drugs;
- Brand name drugs accounted for 9.5% of prescriptions and constituted 21.6% of the total annual spending on prescription drugs;
- For the second year, the Pfizer and Moderna COVID-19 vaccines were amongst the most frequently prescribed brand name drugs and the most costly brand name drugs. Also, this is the first year which shows COVID-19 tests amongst the brand name drugs with the highest year-over-year increase in total spending; and,
- The primary drugs that are driving the increase in the total prescription drug cost spending for 2022 are in the specialty and brand name drug categories. In particular, several drugs used in the management of diabetes or weight loss and biological immunological drugs have risen in the rankings or appeared on the top 25 lists for the first time and are among the most expensive and rapidly expanding drugs.
- Cost sharing structures. According to the California Health Benefits Review Program (CHBRP), payment for use of covered health insurance benefits is shared between the payer (e.g., health plan/insurer or employer) and the enrollee. Common cost-sharing mechanisms include copayments, coinsurance, deductibles, and out-of-pocket maximums (OOPMs) (but do not include premium expenses). Definitions of each are as follows:
- Deductible: The enrollee is responsible for paying the full cost of covered benefits subject to the deductible until the full value of the deductible is paid by the enrollee. The enrollee’s payments towards the deductible accumulate over the course of the plan or policy year. For example, if an enrollee has a $750 deductible, and uses four $250 services that are subject to the deductible throughout the course of the year, the enrollee would pay for the first three services ($250 x 3 = $750) in full. At that point, the deductible would be met and a different form of cost sharing such as a copayment or coinsurance may be applied to the fourth visit, depending on the plan or policy.
- Copayment: A copayment is a flat dollar amount paid by the enrollee per service for services subject to a copayment. Copayments may be applied on their own or to services subject to a deductible after the deductible is met. Copayments are often higher for brand drugs, particularly when a lower-cost bioequivalent generic is available, to discourage their use.
- Coinsurance: Coinsurance is the percentage of the total cost of a service that will be paid by the enrollee. For example, on a $250 service subject to a 10% coinsurance, the enrollee cost sharing would be $25. Coinsurance may be applied on its own or to services subject to deductible after the deductible is met.
- OOPM: The annual OOPM is the maximum an enrollee will spend on cost sharing for covered services in the form of deductibles, copayments, and coinsurance during the plan/policy year. For plans and policies available through Covered California, OOPMs for in-network EHBs are applicable. In 2024, the OOPM limit for self-only coverage is $9,450. If an enrollee has a high-cost hospital stay in the first month of their plan/policy year (whether or not that plan or policy includes a deductible) and reaches their OOPM, the enrollee will not have any other cost sharing for covered services for the remaining 11 months of the plan/policy year.
- Prescription Drug Spending and SB 17 DMHC Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The DMHC considers the total volume of prescription drugs prescribed by health plans and the total cost paid by health plans for these drugs, on both an aggregate spending level and a per member per month basis and compares the annualized data. The DMHC also analyzes how the 25 most frequently prescribed drugs, the 25 most costly drugs, and the 25 drugs with the highest year-over-year increase in total annual spending impacted health plan premiums over the course of the last four years. The most recent report notes the following key findings:
There are varieties of cost-sharing mechanisms that can be applicable to covered benefits. Some health insurance benefit designs incorporate higher enrollee cost sharing to lower premiums. Reductions in allowed copayments, coinsurance, and/or deductibles can shift the cost to premium expenses or to higher cost sharing for other covered benefits. Annual OOPMs for covered benefits limit annual enrollee cost sharing (medical and pharmacy benefits). After an enrollee has reached this limit through payment of coinsurance, copayments, and/or deductibles, insurance pays 100% of the covered services. The enrollee remains responsible for the full cost of any tests, treatments, or services that are not covered benefits. Under current law, some health plans and insurers may design their pharmacy benefit to not allow payments made in association with pharmaceutical drug discount cards or by PAPs from counting towards an enrollee’s copayment, coinsurance, or OOPM.
This bill instead mandates that all such payments would count towards the enrollee’s cost-sharing responsibility.
- Copay accumulator programs. Copayment adjustment programs are a type of pharmacy benefit design that offset the impacts of certain pharmaceutical financial assistance; they operate by prohibiting the contributions made by a third party from counting towards the enrollee’s OOPM. They may be designed to target specific drugs. Copayment adjustment programs are used to encourage the use of lower-cost prescription drugs, drive down drug prices, and reintroduce price sensitivity to enrollees who use financial assistance for OOP costs. There are two types of copayment adjustment programs: copay accumulator programs and copay maximizer combination programs.
- Copay accumulator programs: Prohibit any amounts collected at the point of sale when using financial assistance from a third party for a prescription drug from counting towards their deductible or annual OOPM; and,
- Copay maximizer programs: Amounts collected at the point of sale when using financial assistance from a third party for a prescription drug do not count towards their deductible or annual OOPM; however, the cost share is adjusted to an amount that maximizes the value of the financial assistance from a third party and applied throughout the benefit year.
- Federal guidance on PAPs. According to CHBRP, the Office of Inspector General (OIG) is a federal agency with a mission to provide objective oversight to promote efficiency, effectiveness, economy, and integrity of U.S. Department of Health and Human Services programs, and reduce waste, fraud, and abuse. The OIG has published guidance on the operation of nonprofit organizations offering financial assistance for prescription drugs in an effort to allow for the provision of medically necessary drugs to financially needy patients, and ensure the assistance is provided in a manner that does not conflict with the federal anti-kickback statute or other laws. As part of this effort, pharmaceutical manufacturers are prohibited from influencing enrollees’ drug choices through independent charity organizations; to help prevent this from happening, pharmaceutical manufacturers may not control which drugs an independent charities may offer to patients. The OIG is also concerned about the influence of nonprofit organizations providing financial assistance for prescription drugs on overall drug prices. OIG guidance states that although the agency recognizes that a patient prescribed an expensive drug may have a greater need for financial assistance than a patient prescribed a less expensive alternative, the OIG is concerned that limiting cost-sharing support from these organizations to expensive products may steer patients in a manner that is costly to federal health care programs and may even facilitate increases in drug prices. OIG guidance also specifies that the cost of the particular drug for which the patient is applying for assistance is not an appropriate stand-alone factor in determining individual financial need.
- Federal regulations on copayment adjustment programs. In July 2021, the Centers for Medicare & Medicaid Services’ (CMS) final rule on copayment adjustment programs deferred to states regarding their regulation for health plans sold on the exchanges and in nongrandfathered individual and group health plans sold off exchanges. Health plans and insurers were authorized to count payments associated with drug manufacturer financial assistance towards an enrollee’s cost-sharing limits but were not mandated to do so unless the state regulates them otherwise. The 2021 federal rule encouraged, but did not require, health plans and policies to disclose the use of copayment accumulator programs on websites, brochures, plan documents, and other materials. In September 2023, the U.S. District Court for the District of Columbia vacated, or set aside, this rule. An appeal from the federal government was withdrawn. The federal rule which allows insurers to stop applying the value of prescription drug coupons towards an enrollee’s maximum OOP costs in situations where a generic medication is available and medically appropriate, in order to encourage generic use and result in lower drug spending, applies in the marketplace today.
- Medicare. CMS allows for PAPs to provide assistance to Medicare Part D (prescription drug) enrollees; however, they must operate “outside the Part D benefit.” In other words, the payments made by a pharmaceutical patient assistance program do not count towards a Part D beneficiary’s true OOP cost. CMS uses the true OOP calculation to determine whether a beneficiary has reached the threshold for catastrophic coverage under the Part D benefit, after which Medicare covers all Part D drugs for the remainder of the calendar year.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP reviewed this bill and states the following in its analysis:
- Assumptions: PBMs typically only work with specialty pharmacies, which they either own or have exclusive contracts with, on implementation of copayment adjustment programs. CHBRP assumes that this bill would only impact specialty drugs, which are typically high-cost brand-name drugs. Specialty drugs come in various forms and may be billed under either the pharmacy benefit, medical benefit, or both. The timing of claims processing for specialty drugs varies significantly between those on the pharmacy versus medical benefit. Specialty drugs billed on the pharmacy benefit are processed in real time. In contrast, the billing system for medical benefit drugs is more complex, making it difficult to track claims and, therefore, track payments. In addition, claims for medical benefit drugs can take several weeks to process with third-party insurance. Because of this, it is difficult for PBMs to include medical benefit drugs in copayment adjustment programs. Thus, CHBRP assumes that specialty drugs administered in a medical setting are already compliant and this bill would only impact specialty drugs on the pharmacy benefit. CHBRP also considered how trends in biosimilars might impact assumptions for this bill. The interaction of biosimilar availability and adoption on this bill is potentially mixed. Considerations include the extent to which biosimilars are available from multiple manufacturers, the extent to which biosimilars impact drug prices (including rebates) as well as total member cost-sharing requirements, and the extent to which biosimilars are available and even preferred on formularies developed by PBMs. Biosimilars are a type of biologic medication and may be available at a lower cost than the original biologics (which include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins).
- Enrollees covered. CHBRP estimates the number of specialty prescriptions filled that have drug copay assistance (117,000) would not change due to this bill in the first year. This represents approximately 11,000 enrollees who will be impacted by this bill. Similarly, the average unit cost (for a 30-day fill) for specialty medications of $7,964 would not change from baseline to postmandate.
- Impact on expenditures. Postmandate, some enrollees would reach their OOPM earlier in the year as a result of this bill and would utilize services that they would not have used prior to enactment of the mandate; these additional services would be fully paid for by the health plans/insurers. Overall, this bill would increase total net annual expenditures for the first year by $24,714,000, or 0.02%, for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to a $52,745,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $28,031,000 decrease in enrollee expenses for covered and/or noncovered benefits. It should be noted that total net annual expenditures for the second year identifies an increase of $94,953,000.
Changes in premiums as a result of this bill would vary by market segment. Among DMHC-regulated plans, large-group premiums would increase by 0.03%, individual market premiums would increase by 0.03%, and CalPERS would increase by 0.01%. However, DMHC-regulated small-group premiums would increase by 0.12%. In the CDI-regulated market, the large-group market would face the smallest increase (0.12%), while individual (0.16%) and small group (0.17%) would have the highest increase across all markets.
CHBRP estimates this bill would result in enrollees in non-CalPERS commercial plans in all markets to pay less in OOP expenses. On average, DMHC-regulated large-group enrollees would experience a $0.10 reduction in enrollee expenses on the low end, with small-group DMHC-regulated enrollees experiencing a $0.48 decrease in enrollee expenses on the high end. For CDI-regulated enrollees, those with small-group ($0.92 decrease) and individual market ($0.68 decrease) policies would see the largest reduction in OOP expenses, while enrollees in large-group policies would experience $0.48 in reduced enrollee expenses on average. Overall, enrollee expenses would decrease by $28,031,000 across all markets. Due to the decreases in cost sharing, measurable public health impacts at the population level may occur if it results in increased adherence to a prescription drug.- CalPERS. Postmandate, for enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.01% ($0.0066 per member per month, $429,000 total increase in expenditures).
- Covered California. Postmandate, premiums for enrollees in individual plans purchased through Covered California would increase by less than 0.01% (approximately $180,000 increase in total expenditures).
- Number of Uninsured in California. CHBRP expects no measurable change in the number of uninsured persons due to the enactment of this bill.
- EHBs. This bill does not appear to exceed the EHB definition, as all health plans and insurance carriers in California are already required to cover outpatient prescription drugs.
- Long-term impacts. In the longer term, CHBRP anticipates that this bill would incentivize manufacturers to increase funding to drug copay assistance through nonprofit organizations. Manufacturers would stand to benefit from increased drug copay assistance because by removing barriers to patient access to high-cost medications, manufacturers may increase the overall demand for specialty medications. Health plans and insurers may respond by removing specific high-cost specialty drugs that have therapeutic equivalent drugs from their formulary. Off-formulary drugs are not considered covered benefits, and therefore this bill would not apply to these drugs.
- Cost impacts. One key aspect of this bill is the degree to which patients may be willing to switch to alternative therapies when presented with an opportunity to reduce OOP expenditures. Drug copay assistance may influence patient behavior, as patients with drug copay assistance may be less likely to search for lower-cost, alternative treatment options. Furthermore, these programs may even minimize or eliminate cost sharing for all other medical services throughout the year if the OOPM is reached. The presence of these programs may have the long-term potential to encourage patients to continue a specific therapy even as less costly, equivalent therapies become available. Therefore, these programs may have the potential to increase overall costs for drugs over time. Another key consideration of this bill is the degree to which the mandate impacts patients with chronic disease versus terminal diseases. Due to the ongoing nature of treatments for chronic disease, the potential for higher utilization is greater for medications for chronic conditions than those for terminal diseases. CHBRP also notes that this bill may address inequalities because of the current consequences of cost sharing on low-income patients. At baseline, some patients may face financial hardships in order to receive needed treatments or even postpone treatment if nonprofit organizations have insufficient drug copay assistance to meet patient demand. Assuming this bill leads to an influx of additional financial contributions from pharmaceutical manufacturers and other organizations to copay assistance programs, the mandate may benefit those who would otherwise suffer financial hardship and may reduce health care disparities amongst lower income populations with commercial insurance. In addition, postmandate, some patients may no longer be compelled to pay up front for their prescriptions, as this bill eliminates the requirement to cover the deductible and OOPM for these patients, through drug copay assistance and a card processed by the PBM at the point of sale. This would benefit those who would otherwise suffer financial hardship, and may reduce health care disparities amongst lower-income populations with commercial insurance. In Year 2 (2026), CHBRP assumes that this factor would lead to increased utilization. It stands to reason that in the long run, this bill may improve the health status of patients who would not have otherwise received treatment.
- Other states. Massachusetts has also banned the use of discounts or other reductions for prescription drugs when a generic equivalent is available. Twenty states, including Arizona, Arkansas, Colorado, Connecticut, Delaware, Georgia, Illinois, Kentucky, Louisiana, Maine, New Mexico, New York, North Carolina, Oklahoma, Tennessee, Texas, Vermont, Virginia, Washington, and West Virginia, and the District of Columbia and Puerto Rico have enacted legislation banning copayment adjustment programs.
- Copay accumulator programs. Copayment adjustment programs are a type of pharmacy benefit design that offset the impacts of certain pharmaceutical financial assistance; they operate by prohibiting the contributions made by a third party from counting towards the enrollee’s OOPM. They may be designed to target specific drugs. Copayment adjustment programs are used to encourage the use of lower-cost prescription drugs, drive down drug prices, and reintroduce price sensitivity to enrollees who use financial assistance for OOP costs. There are two types of copayment adjustment programs: copay accumulator programs and copay maximizer combination programs.
- SUPPORT. The ALS Association, California Rheumatology Alliance, Cystic Fibrosis Research Institute, Hemophilia Council of California and Sickle Cell Disease Foundation (cosponsors) write that many Californians with chronic and terminal conditions rely on PAPs to afford their vital medications when there is no generic equivalent available to help them manage their complex or serious conditions and avoid costly health complications. Copay assistance provided from third-party sources for specific medications should not be confused with discounts, product vouchers or coupons that are available for general use and yield a percentage-based discount off the list price of a prescription drug. Unfortunately, nearly half of California-regulated commercial health plans and PBMs have copay accumulator policies, which are often obscurely stated in patients’ annual health plan benefit summaries, to prevent copay assistance from counting towards patients’ annual deductibles and maximum OOP cost-sharing. Moreover, health plans and PBMs are increasingly moving therapies covered through the pharmacy benefit to the medical benefit, which typically has a much higher copay and thus further increases the financial burden on patients who depend on such therapies. According to the co-sponsors, commercial health plans and PBMs that utilize copay accumulators are turning the financial copay assistance for medications intended to help patients in need into a financial windfall for themselves since they collect the third-party source payments made on patients’ behalf while also requiring these patients to pay their full annual OOP cost-share obligations, thereby double dipping. The adverse effect of copay accumulators is to nullify the financial relief that eligible patients would normally receive from participating in PAPs, putting these patients in greater harm when they discover that they can no longer afford their vital medications and raising overall health care costs due to unnecessary complications. This is also a health equity issue since copay accumulators have a disproportionate impact on the most vulnerable patients, including the underinsured and individuals with chronic or terminal conditions who often rely on multiple treatments to manage their illness and who have a higher OOP health care spend year-after-year than healthier patients. The co-sponsors conclude that this bill will ensure that patients who rely on costly treatments no longer must choose between filling their prescriptions or paying for other necessities.
- OPPOSITION. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans (collectively “opposition”) write that everyone should be able to get the medications they need at a cost they can afford. But drug prices continue to rise with no end in sight, and hardworking families feel the consequences every day. Prescription drug costs now represent over 22 cents out of every dollar of premium spent on health care. Drug manufacturers acknowledge their drugs are unaffordable for patients, but rather than choose to lower their prices for everyone, they point to their PAPs which offer copay coupons. Coupons are offered only to a narrow set of patients, for a narrow selection of drugs, and often only for a limited time. Once the patient hits their deductible, drugmakers discontinue the patient’s coupons. According to the opposition, this scheme allows drugmakers to keep their underlying prices hidden from patients, while keeping their costs extremely high for employers and consumers who end up paying much more in premiums and cost-sharing. The federal government considers copay coupons illegal kickbacks in federal health care programs like Medicare and Medicaid because these coupons induce a patient to use a specific drug. To counter the market manipulation from coupons, health plans and insurers have worked together with employers to develop programs to hold drug companies accountable, to shed light on these pricing schemes, and keep costs low for Californians. Such programs help restore the balance in the system by allowing patients to use manufacturer coupons to save money at the pharmacy counter, but does not count the amount the drug manufacturer has paid for the drug (through the coupon) towards the patient’s deductible or OOPM. Legislation like this bill that bans these programs by requiring health plans and insurers to count third-party payments towards an enrollee’s cost sharing obligations will eliminate incentives for drug companies to lower prices. The opposition concludes that as a result, drug companies will make more money while California families and businesses continue to foot the bill through higher premiums, higher OOP expenses, and higher federal insurance subsidies.
- RELATED LEGISLATION. SB 966 (Wiener) requires a PBM, as defined by the bill, to apply for and obtain a license from the Board of Pharmacy (board) to operate as a PBM. Requires a PBM, on or before April 1, 2027, and annually thereafter, to file with the board a report containing specified information. Prohibits the report from disclosure to the public. Requires the board, on or before August 1, 2027, and annually thereafter, to submit a report to the Legislature based on the reports submitted by licensees, and requires the board to post the report on the board’s internet website. Imposes specified duties, including prohibiting a PBM from deriving income from PBM services, except as specified. SB 966 was recently amended in Senate Business, Professions and Economic Development Committee and is pending in Senate Health Committee.
- PREVIOUS LEGISLATION.
- AB 874 (Weber) of 2023 was similar to this bill but was never heard in Assembly Health Committee.
- SB 873 (Bradford) of 2023 would have required an enrollee’s or insured’s defined cost sharing for each prescription drug to be calculated at the point of sale based on a price that is reduced by an amount equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. Would have required DMHC and CDI to submit an annual report on the impact of these provisions to the appropriate policy committees of the Legislature, as specified. SB 873 was held on suspense in the Assembly Appropriations Committee.
- AB 948 (Berman), Chapter, Statutes of 2023, makes permanent existing law provisions that prohibit the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription from exceeding $250 for a supply of up to 30 days or $500 for bronze products, except as specified.
- AB 933 (Daly) of 2021 is substantially similar to SB 873 and was held on suspense in the Assembly Appropriations Committee.
- AB 290 (Wood), Chapter 862, Statutes of 2019, requires a health plan or an insurer that provides a policy of health insurance to accept payments from specified third-party entities, including an Indian tribe or a local, state, or federal government program. Requires a financially interested entity, as defined, other than those entities, that is making a third-party premium payment, to provide that assistance and to perform other related duties, including disclosing to the plan or the insurer the name of the enrollee or insured, as applicable, for each plan or policy on whose behalf a third-party premium payment will be made. Requires each plan or insurer to provide to the appropriate department information regarding premium payments by financially interested entities and reimbursement for services to providers, and would set forth standards governing the reimbursement of financially interested providers, including, but not limited to, chronic dialysis clinics, that meet certain criteria. Requires reimbursement to contracted providers to be the higher of the Medicare reimbursement rate or the rate determined pursuant to an independent dispute resolution process, as prescribed.
- AB 315 (Wood), Chapter 905, Statutes of 2018, requires health plans that contract with PBMs to register with the DMHC.
- AB 265 (Wood), Chapter 611, Statutes of 2017, prohibits prescription drug manufacturers from offering discounts or other reduction in an individual's OOP expenses associated with his or her insurance coverage, if a lower cost therapeutically equivalent generic drug is available. Specifies a number of exceptions that allow discounts even if a lower cost therapeutically equivalent generic drug is available.
- SB 17 (Hernandez), Chapter 603, Statutes of 2017, requires health plans and insurers that report rate information through the existing large and small group rate review process to also report specified information related to prescription drug pricing to DMHC and CDI. Requires DMHC and CDI to compile specified information into a consumer-friendly report that demonstrates the overall impact of drug costs on health care premiums. Requires drug manufacturers to notify specified purchasers, in writing at least 90 days prior to the planned effective date, if it is increasing the wholesale acquisition cost of a prescription drug by specified amounts. Requires drug manufacturers to notify the the Department of Health Care Access and Information (HCAI) three days after FDA approval when introducing a new drug to market, as specified. Requires drug manufacturers to provide specified information to HCAI related to the drug’s price.
- AMENDMENTS. The Committee is recommending the following amendments to address some of the potential unintended consequences raised by the CHBRP analysis:
- Add a sunset and authorize the regulators to conduct an analysis of this bill and its impact to consumers and whether or not the Legislature should eliminate the sunset;
- Update SB 17 reporting to include PAPs;
- Require notices to enrollees on the availability of the PAP during the contract period; and,
- Limit this bill to prescription drugs.
- COMMENTS.
- Specialty Drugs. As part of this analysis, CHBRP assumed that compliance with this mandate will impact only specialty medications, as PBMs rely on specialty pharmacies to handle pricing adjustments at point-of-sale to administer these programs. As the recent SB 17 report pointed out, the cost of specialty drugs continues to be a driver of overall health care costs. In the second year of implementation, total net annual expenditures is $94,953,000. As drafted, there is nothing in this bill that guarantees or controls how much manufacturers could increase their prices. To address concerns that PAPs may facilitate increased in drug prices, should this bill be amended such that PAPs must be applied towards the enrollee’s OOPM only if there is no generic equivalent and consistent with AB 265 which prohibits prescription drug coupons when there is a generic available?
- Prescription Drug Coupons. This bill, as introduced, excluded general manufacturer coupons. Recent amendments now specify, “third-party patient assistance program does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug.” Since this language is different from CHBRP’s current analysis, the Committee may wish to request an updated analysis to reflect the current language of this bill.
REGISTERED SUPPORT / OPPOSITION:
Support
ALS Association (cosponsor)
California Rheumatology Alliance (cosponsor)
Cystic Fibrosis Research Institute (cosponsor)
Hemophilia Council of California (cosponsor)
Sickle Cell Disease Foundation (co-sponsor)
AIDS Healthcare Foundation
Aim At Melanoma Foundation
Aimed Alliance
Alliance for Gout Awareness
Alliance for Patient Access
American Cancer Society Cancer Action Network INC.
American Diabetes Association
Arthritis Foundation
Association for Clinical Oncology
Association of Northern California Oncologists
Association of Women in Rheumatology (AWIR)
California Academy of Physician Assistants
California Black Health Network
California Chapter American College of Cardiology
California Chronic Care Coalition
California Life Sciences
California Medical Association
California Pharmacists Association
California Retired Teachers Association
California Society of Dermatology & Dermatologic Surgery
California Society of Plastic Surgeons
California Urological Association
Cancer Support Community San Francisco Bay Area
Center for Inherited Blood Disorders
Central California Hemophilia Foundation
Children's Hospital Los Angeles
Children's Specialty Care Coalition
Chronic Care Policy Alliance
Chronic Disease Coalition
Community Oncology Alliance (COA)
Crohns and Colitis Foundation
Cystic Fibrosis Foundation
Everylife Foundation for Rare Diseases
Global Healthy Living Foundation
Head
Hemophilia Federation of America
Hemophilia Foundation of Northern California
Hemophilia Foundation of Southern California
HIV + Hepatitis Policy Institute
ICAN, International Cancer Advocacy Network
Infusion Access Foundation (IAF)
International Foundation for Autoimmune and Inflammatory Arthritis
Looms for Lupus
Lung Cancer Foundation of America
Lungevity Foundation
Lupus and Allied Diseases Association, INC.
Medical Oncology Association of Southern California
Movement Disorders Policy Coalition
National Bleeding Disorders Foundation
National Health Law Program
National Infusion Center Association (NICA)
National Multiple Sclerosis Society, Ms-can
National Psoriasis Foundation
Oncology Nursing Society
Osteopathic Physicians and Surgeons of California
Spondylitis Assocation of America
Support Fibromyalgia Network
The AIDS Institute
The Defeating Epilepsy Foundation
The Hemophilia Association of San Diego County
UCSF Adult Hemophilia Treatment Center
Vision Health Advocacy Coalition
We Win Foundation
Opposition
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
Pharmaceutical Care Management Association
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Date of Hearing: May 15, 2024
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 2180
Author:(Weber) – As Amended Ver:April 30, 2024
Policy Committee: | Health | Vote: | 16 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health plan or insurer, or a pharmacy benefit manager (PBM), to apply toward the enrollee’s annual cost sharing requirement, any amounts the enrollee or third-party patient assistance program (PAP) has paid for prescription drugs, if that enrollee or insured has a chronic disease or terminal illness. This bill also requires health plans and insurers to report certain prescription drug cost information to state regulators.
The bill applies to health plan and insurance contracts issued, amended, or renewed on or after January 1, 2025, and is repealed on January 1, 2035.
Specifically, this bill:
- Requires a health plan, insurer, or PBM that administers pharmacy benefits for a health plan or insurer to apply any amounts paid by the enrollee or insured (“enrollee”) or PAP for prescription drugs towards the enrollee’s cost sharing requirement, to the extent permitted by federal law, and consistent with existing law relating to prescription drug discount prohibitions.
- Applies to only those enrollees who have a chronic disease or terminal illness, as defined.
- Requires a health plan or insurer, when calculating an enrollee or insured’s overall contribution to the annual limitation on cost sharing, to include expenditures for any item or service covered by the health plan or insurer, and include within a category of essential health benefits (EHBs), which expenditures will be considered expenditures for essential health coverage benefits covered under the contract or policy.
- Specifies that if under federal law, 1), above, would result in health savings account (HSA) ineligibility, this requirement applies for HSA-qualified high deductible health plans (HDHP) with respect to the deductible of a policy after the enrollee or insured has satisfied the minimum deductible under federal law, as specified.
- Requires a health plan or insurer that reports rate information to report specified information to the Department of Managed Health Care (DMHC) or the California Department of Insurance (CDI), including the 25 most frequently prescribed drugs, the 25 most costly drugs, the 25 drugs with the highest year-over-year increase in total annual plan spending, the 25 most frequently prescribed drugs with a PAP by total plan spending, and the aggregate dollar amount of all PAPs collected from third-party entities that are attributable to enrollee drug utilization.
- Requires DMHC and CDI to prepare and provide to the appropriate policy committees of the Legislature, by March 31, 2034, a report on the effects of this bill on drug prices and health care premiums, and the departments’ recommendations on whether the repeal date on this bill should be deleted. Requires DMHC and CDI to also compile the information from 5), above, and prepare for the public and the Legislature a report on the impact of drug costs and third-party PAPs on premiums, cost sharing, and payments to PBMs.
- Defines third-party PAP to include “manufacturer or charitable cost-sharing or copay assistance programs that provide financial assistance intended to assist patients in paying their out-of-pocket (OOP) cost-sharing obligations for prescription drugs.” Also defines cost-sharing requirement, PBM, chronic disease, and terminal illness.
FISCAL EFFECT:
- DMHC estimates the total cost of this bill to be approximately $435,000 in fiscal year (FY) 2024-25, $528,000 in FY 2025-26, $515,000 in FY 2026-27, $516,000 in FY 2027-28, $517,000 in FY 2028-29, and $518,000 in FYs 2029-30 through 2034-35 (Managed Care Fund). The bill’s costs will be incurred by different offices within DMHC for short-term workload to conduct legal research, draft legal memoranda and promulgate regulations to clarify the new requirements, revise reporting templates, review health plan filings, and compile data for annual reporting and compliance. Costs also include software licensing.
- CDI estimates costs of $6,000 in FY 2024-25 and $18,000 in FY 2025-26 (Insurance Fund).
- Annual costs to CalPERS of $540,000 in the first year post-mandate and $1.7 million in the second year post-mandate (Public Employees Health Care Fund, other special funds). The California Health Benefits Review Program (CHBRP) estimates this bill will increase premiums by $898,000 in the first year and $2.8 million in the second year, and the state pays for approximately 60% of these costs.
COMMENTS:
- Purpose. This bill is co-sponsored by the ALS Association, California Rheumatology Alliance, Cystic Fibrosis Research Institute, Hemophilia Council of California, and the Sickle Cell Disease Foundation. According to the author:
This bill will have California join 16 other states and Puerto Rico in banning the copay accumulator programs. These programs are used by health insurers and PBMs to prevent copay assistance given to patients from counting towards their deductible and maximum OOP spending. This practice reduces the cost to payers while placing an extreme financial burden on patients, who then are forced to pay OOP to reach their full deductibles or forego their life-saving medications because they can’t afford it. Copay assistance is provided by drug manufacturers, charitable foundations and other third parties to help patients pay for their prescriptions, sometimes saving them thousands of dollars. However, health plans and PBMs are keeping the value of the copay assistance, turning the help given to patients into more profit for themselves. The author concludes that this bill would ban the practice of copay accumulator programs to lift the burden from patients.
- Background. SB 17 (Hernandez), Chapter 603, Statutes of 2017, requires health plans in the commercial market to annually report their prescription drug costs to DMHC. The most recent SB 17 report notes the following key findings:
- Health plans paid about $12.1 billion for prescription drugs in 2022, an increase of almost $1.3 billion, or 12.3%, from 2021. Since 2017, prescription drug costs paid by health plans increased by $3.4 billion, or 39%.
- Prescription drugs accounted for 14.2% of total health plan premiums in 2022, an increase from 13.3% in 2021.
- Manufacturer drug rebates totaled about $2.1 billion in 2022, up from $1.7 billion in 2021 and $1.4 billion in 2020.
- While specialty drugs accounted for only 1.6% of all prescription drugs dispensed, they accounted for 64% of total annual spending on prescription drugs.
- Generic drugs accounted for 89% of all prescribed drugs but only 14.4% of the total annual spending on prescription drugs.
- Specialty and brand name drugs drove the increase in total prescription drug cost spending for 2022. In particular, several drugs used in the management of diabetes or weight loss and biological immunological drugs have risen in the rankings or appeared on the top 25 lists for the first time and are among the most expensive and rapidly expanding.
- CHBRP Analysis. CHBRP projects that if this bill passes, in the first year, premiums for employer-sponsored insurance will increase by over $51 million, which represents a 0.08% change. Premiums paid by CalPERS would increase by $899,000. CHBRP estimates premiums paid by enrollees for individually purchased insurance would increase by $11 million, and enrollees in group insurance would pay over $17 million more, an increase of 0.09%.
CHBRP also projects out-of-pocket expenses for enrollees would decrease by $34 million, or 0.22% cost sharing. This reduction in costs would benefit only those with chronic or terminal diseases. The net change in expenditures would be an increase of $47 million.
In the second year post-mandate, CHBRP projects overall costs will change as follows: total expenditures will increase by $121 million, employer-sponsored health and insurance plan premiums (excluding CalPERS) will increase by over $97 million, enrollee premiums will increase by $33 million for group insurance and $30 million for individual insurance, and enrollee out-of-pocket expenses will decrease by nearly $43 million.
CHBRP projects that in the long term, this bill will incentivize manufacturers to increase the number of coupons available for specialty drugs, and to a lesser extent, the funding to drug copay assistance programs through nonprofit organizations. CHRBP states drug manufacturers stand to benefit from increased coupons and drug copay assistance because removing barriers to patient access to high-cost medications may increase the overall demand for specialty medications.
CHBRP notes this bill might address inequalities. At baseline, some patients may face financial hardships to receive needed treatments, or postpone treatment if nonprofit organizations have insufficient drug copay assistance to meet patient demand. Assuming this bill leads to an influx of financial contributions from pharmaceutical manufacturers and other organizations to drug copay assistance programs, or an increase in the number of available drug manufacturer coupons, this bill might benefit those who would otherwise suffer financial hardship.
- Support. The sponsors of this bill write that many Californians with chronic and terminal conditions rely on PAPs to afford medications when there is no generic equivalent available. The sponsors write that nearly half of California-regulated commercial health plans and PBMs have copay accumulator policies to prevent copay assistance from counting towards enrollees’ annual deductibles and maximum OOP cost-sharing. The sponsors add that health plans and PBMs are increasingly moving therapies covered through the pharmacy benefit to the medical benefit, which typically has a much higher copay and thus further increases the financial burden on patients who depend on such therapies. The sponsors contend that commercial health plans and PBMs that utilize copay accumulators are turning the financial copay assistance for medications intended to help patients in need into a financial windfall for themselves since they collect the third-party source payments made on patients’ behalf while also requiring these patients to pay their full annual OOP cost-share obligations. The sponsors argue copay accumulators nullify the financial relief that eligible patients would normally receive from participating in PAPs, and this is a health equity issue since copay accumulators have a disproportionate impact on the most vulnerable patients, who often rely on multiple treatments to manage their illness and who have high OOP spending.
- Opposition. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans (collectively “opposition”) write that drug manufacturers acknowledge their drugs are unaffordable for patients, but rather than choose to lower their prices for everyone, they point to their PAPs, which offer copay coupons. PAPs offer coupons only to a narrow set of patients, for a narrow selection of drugs, and often only for a limited time. Once the patient hits their deductible, drugmakers discontinue the patient’s coupons. The opposition argues this scheme allows drugmakers to keep their underlying prices hidden from patients, while keeping their costs extremely high for employers and consumers who end up paying much more in premiums and cost-sharing. The opposition notes that the federal government considers copay coupons illegal kickbacks in federal programs like Medicare and Medicaid because these coupons induce a patient to use a specific drug. To counter the market manipulation from coupons, health plans and insurers have worked together with employers to develop programs to hold drug companies accountable, to shed light on these pricing schemes, and keep costs low for Californians. Such programs help restore the balance in the system by allowing patients to use manufacturer coupons to save money at the pharmacy counter, but does not count the amount the drug manufacturer has paid for the drug (through the coupon) towards the patient’s deductible or OOP maximum. The opposition argues legislation like this bill that bans these programs by requiring health plans and insurers to count third-party payments towards an enrollee’s cost sharing obligations will eliminate incentives for drug companies to lower prices. The opposition concludes that as a result, drug companies will make more money while California families and businesses continue to foot the bill through higher premiums, higher OOP expenses, and higher federal insurance subsidies.
- Related Legislation.
- SB 966 (Wiener) requires a PBM to apply for and obtain a license from the Board of Pharmacy (board) and requires a PBM to annually file with the board a report containing specified information and requires the board to annually submit a report to the Legislature based on the reports submitted by licensees. SB 966 is pending in Senate Appropriations Committee.
- AB 874 (Weber) is similar to this bill. AB 874 was referred to, but not heard in, Assembly Health Committee.
- SB 873 (Bradford) of 2023 requires an enrollee’s defined cost sharing for each prescription drug to be calculated at the point of sale based on a price that is reduced by an amount equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. SB 873 was held on this committee’s suspense file.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 23, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 2180
Author:((Weber) – As Amended Ver:April 10, 2024
SUBJECT: Health care coverage: cost sharing.
SUMMARY: Requires a health plan, insurer, or pharmacy benefit manager (PBM) to apply any amounts paid by the enrollee, insured, or third party patient assistance program (PAP) towards the enrollee or insured’s cost sharing requirement for those who have a chronic disease or terminal illness. Specifically, this bill:
- Requires a health plan, insurer, or PBM that administers pharmacy benefits for a health plan or insurer to apply any amounts paid by either the enrollee or insured or PAP to the enrollee or insured’s cost sharing requirement, to the extent permitted by federal law, and consistent with existing law relating to prescription drug discount prohibitions. Limits requirements to only those enrollees or insureds who have a chronic disease or terminal illness.
- Requires a health plan or insurer to include expenditures for any item or service covered by the health plan or insurer, and include within a category of essential health benefits (EHBs) when calculating an enrollee or insured’s overall contribution to the annual limitation on cost sharing set forth in existing federal law.
- Specifies that if under federal law, 1) above would result in health savings account (HSA) ineligibility, this requirement to apply for HSA-qualified high deductible health plans (HDHP) with respect to the deductible of a policy after the enrollee or insured has satisfied the minimum deductible under federal law, except with respect to items or services that are preventive care, as specified.
- Exempts provisions of this bill from self-insured employer plans governed by the Employee Retirement Income Security Act of 1974.
- Defines the following:
- Cost-sharing requirement as any copayment, coinsurance, deductible, or annual limitation on cost-sharing, including a limitation subject to federal law, required by, or on behalf of, an enrollee or insured in order to receive a specific health care service, including a prescription drug, covered by a health plan contract or insurance policy;
- PBM as a person or business that administers the prescription drug or device program of one or more health plans or insurers on behalf of a third party in accordance with a pharmacy benefit program. Includes any agent or representative of a PBM hired or contracted by the PBM to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a PBM;
- PAP to include, but is not limited to, manufacturer or charitable cost-sharing or copay assistance programs that provide financial assistance intended to assist patients in paying their out-of-pocket (OOP) cost-sharing obligations for prescription drugs. Third-party PAP does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug;
- Chronic disease as conditions that have a tendency to last one year or more and require ongoing medical attention or limit activities of daily living or both; and,
- Terminal illness as a medical condition that is life-limiting and expected to result in death.
EXISTING LAW:
- Establishes DMHC to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) §1340, et seq., and Insurance Code (INS) §106, et seq.]
- Establishes as California's EHB benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and 10 Patient Protection and Affordable Care Act mandated benefits, including prescription drugs. [HSC §1367.005 and INS §10112.27]
- Prohibits, with respect to an individual or group health plan contract or health insurance policy that covers EHBs, the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription for a supply of up to 30 days from exceeding $250; for a product with an actuarial value at or equivalent to a Bronze level, limits cost sharing to not more than $500 for a supply of up to 30 days; and for a HDHP the $250 or $500 limits apply only after an enrollee’s deductible is met. [HSC §1342.73 and INS §10123.1932]
- Requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums. [HSC §1356.243 and INS §10123.205]
- Requires health plans and insurers, for all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, to report:
- The 25 most frequently prescribed drugs;
- The 25 most costly drugs by total annual plan spending; and,
- The 25 drugs with the highest year-over-year increase in total annual plan spending. [HSC §1356.243 and INS §10123.205]
- Requires DMHC and CDI to compile the information from 5) above into a report for the public and Legislators where the data is aggregated and does not reveal information specific to individual plans. Requires the report to be published on DMHC’s and CDI’s website. [HSC §1356.243 and INS §10123.205]
- Defines a PBM as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs. [HSC §1385.001]
- Requires a health plan that contracts with a PBM to require the PBM to comply with specified requirements including register with DMHC and exercise good faith and fair dealing in the performance of its duties. [HSC §1385.004 and §1385.005]
- Requires the failure by a health plan to comply with PBM contractual requirements to constitute grounds for disciplinary action. Requires the DMHC Director, as appropriate, to investigate and take enforcement action against a health plan that fails to comply with these requirements and to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. [HSC §1385.006]
- Prohibits a person who manufactures a prescription drug from offering in the state a discount, repayment, product voucher, or other reduction in an individual’s OOP expenses associated with his or her health insurance, health plan, or other health coverage, including, but not limited to, a copayment, coinsurance, or deductible, for a prescription drug if a lower cost generic drug is covered under the individual’s health insurance, health plan, or other health coverage on a lower cost-sharing tier that is designated to be therapeutically equivalent as indicated by the United States Food and Drug Administration’s (FDA) “Approved Drug Products with Therapeutic Equivalence Evaluations.” [HSC §132000]
- Exempts from 9) above, the a single-tablet drug regimen for treatment or prevention of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) that is as effective as a multitablet regimen, unless, consistent with clinical guidelines and peer-reviewed scientific and medical literature, the multitablet regimen is clinically equally effective or more effective and is more likely to result in adherence to the drug regimen; and, an individual who has completed any applicable step therapy or prior authorization requirements for the branded prescription drug as mandated by the individual’s health insurer, health plan, or other health coverage from the prohibition in 9) above. [HSC §132004]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill will have California join 16 other states and Puerto Rico in banning the copay accumulator programs. These programs are used by health insurers and PBMs to prevent copay assistance given to patients from counting towards their deductible and maximum OOP spending. This practice reduces the cost to payers while placing an extreme financial burden on patients, who then are forced to pay OOP to reach their full deductibles or forego their life-saving medications because they can’t afford it. Copay assistance is provided by drug manufacturers, charitable foundations and other third parties to help patients pay for their prescriptions, sometimes saving them thousands of dollars. However, health plans and PBMs are keeping the value of the copay assistance, turning the help given to patients into more profit for themselves. The author concludes that this bill would ban the practice of copay accumulator programs to lift the burden from patients
- BACKGROUND.
- Prescription Drug Spending and SB 17 DMHC Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The DMHC considers the total volume of prescription drugs prescribed by health plans and the total cost paid by health plans for these drugs, on both an aggregate spending level and a per member per month basis and compares the annualized data. The DMHC also analyzes how the 25 most frequently prescribed drugs, the 25 most costly drugs, and the 25 drugs with the highest year-over-year increase in total annual spending impacted health plan premiums over the course of the last four years. The most recent report notes the following key findings:
- Health plans paid about $12.1 billion for prescription drugs in 2022, an increase of almost $1.3 billion, or 12.3%, from 2021. Since 2017, prescription drug costs paid by health plans increased by $3.4 billion or 39%;
- Prescription drugs accounted for 14.2% of total health plan premiums in 2022, an increase from 13.3% in 2021;
- Total prescription drug costs increased by 12.3% in 2022, whereas total medical expenses increased by 7.9%. Overall, total health plan premiums increased by 4.4% from 2021 to 2022;
- Manufacturer drug rebates totaled approximately $2.068 billion, up from $1.674 billion in 2021 and $1.437 billion in 2020. This represents about 17.1% of the $12.1 billion spent on prescription drugs in 2022;
- While specialty drugs accounted for only 1.6% of all prescription drugs dispensed, they accounted for 64% of total annual spending on prescription drugs;
- Generic drugs accounted for 88.9% of all prescribed drugs but only 14.4% of the total annual spending on prescription drugs;
- Brand name drugs accounted for 9.5% of prescriptions and constituted 21.6% of the total annual spending on prescription drugs;
- For the second year, the Pfizer and Moderna COVID-19 vaccines were amongst the most frequently prescribed brand name drugs and the most costly brand name drugs. Also, this is the first year which shows COVID-19 tests amongst the brand name drugs with the highest year-over-year increase in total spending; and,
- The primary drugs that are driving the increase in the total prescription drug cost spending for 2022 are in the specialty and brand name drug categories. In particular, several drugs used in the management of diabetes or weight loss and biological immunological drugs have risen in the rankings or appeared on the top 25 lists for the first time and are among the most expensive and rapidly expanding drugs.
- Cost sharing structures. According to the California Health Benefits Review Program (CHBRP), payment for use of covered health insurance benefits is shared between the payer (e.g., health plan/insurer or employer) and the enrollee. Common cost-sharing mechanisms include copayments, coinsurance, deductibles, and out-of-pocket maximums (OOPMs) (but do not include premium expenses). Definitions of each are as follows:
- Deductible: The enrollee is responsible for paying the full cost of covered benefits subject to the deductible until the full value of the deductible is paid by the enrollee. The enrollee’s payments towards the deductible accumulate over the course of the plan or policy year. For example, if an enrollee has a $750 deductible, and uses four $250 services that are subject to the deductible throughout the course of the year, the enrollee would pay for the first three services ($250 x 3 = $750) in full. At that point, the deductible would be met and a different form of cost sharing such as a copayment or coinsurance may be applied to the fourth visit, depending on the plan or policy.
- Copayment: A copayment is a flat dollar amount paid by the enrollee per service for services subject to a copayment. Copayments may be applied on their own or to services subject to a deductible after the deductible is met. Copayments are often higher for brand drugs, particularly when a lower-cost bioequivalent generic is available, to discourage their use.
- Coinsurance: Coinsurance is the percentage of the total cost of a service that will be paid by the enrollee. For example, on a $250 service subject to a 10% coinsurance, the enrollee cost sharing would be $25. Coinsurance may be applied on its own or to services subject to deductible after the deductible is met.
- OOPM: The annual OOPM is the maximum an enrollee will spend on cost sharing for covered services in the form of deductibles, copayments, and coinsurance during the plan/policy year. For plans and policies available through Covered California, OOPMs for in-network EHBs are applicable. In 2024, the OOPM limit for self-only coverage is $9,450. If an enrollee has a high-cost hospital stay in the first month of their plan/policy year (whether or not that plan or policy includes a deductible) and reaches their OOPM, the enrollee will not have any other cost sharing for covered services for the remaining 11 months of the plan/policy year.
- Prescription Drug Spending and SB 17 DMHC Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The DMHC considers the total volume of prescription drugs prescribed by health plans and the total cost paid by health plans for these drugs, on both an aggregate spending level and a per member per month basis and compares the annualized data. The DMHC also analyzes how the 25 most frequently prescribed drugs, the 25 most costly drugs, and the 25 drugs with the highest year-over-year increase in total annual spending impacted health plan premiums over the course of the last four years. The most recent report notes the following key findings:
There are varieties of cost-sharing mechanisms that can be applicable to covered benefits. Some health insurance benefit designs incorporate higher enrollee cost sharing to lower premiums. Reductions in allowed copayments, coinsurance, and/or deductibles can shift the cost to premium expenses or to higher cost sharing for other covered benefits. Annual OOPMs for covered benefits limit annual enrollee cost sharing (medical and pharmacy benefits). After an enrollee has reached this limit through payment of coinsurance, copayments, and/or deductibles, insurance pays 100% of the covered services. The enrollee remains responsible for the full cost of any tests, treatments, or services that are not covered benefits. Under current law, some health plans and insurers may design their pharmacy benefit to not allow payments made in association with pharmaceutical drug discount cards or by PAPs from counting towards an enrollee’s copayment, coinsurance, or OOPM.
This bill instead mandates that all such payments would count towards the enrollee’s cost-sharing responsibility.
- Copay accumulator programs. Copayment adjustment programs are a type of pharmacy benefit design that offset the impacts of certain pharmaceutical financial assistance; they operate by prohibiting the contributions made by a third party from counting towards the enrollee’s OOPM. They may be designed to target specific drugs. Copayment adjustment programs are used to encourage the use of lower-cost prescription drugs, drive down drug prices, and reintroduce price sensitivity to enrollees who use financial assistance for OOP costs. There are two types of copayment adjustment programs: copay accumulator programs and copay maximizer combination programs.
- Copay accumulator programs: Prohibit any amounts collected at the point of sale when using financial assistance from a third party for a prescription drug from counting towards their deductible or annual OOPM; and,
- Copay maximizer programs: Amounts collected at the point of sale when using financial assistance from a third party for a prescription drug do not count towards their deductible or annual OOPM; however, the cost share is adjusted to an amount that maximizes the value of the financial assistance from a third party and applied throughout the benefit year.
- Federal guidance on PAPs. According to CHBRP, the Office of Inspector General (OIG) is a federal agency with a mission to provide objective oversight to promote efficiency, effectiveness, economy, and integrity of U.S. Department of Health and Human Services programs, and reduce waste, fraud, and abuse. The OIG has published guidance on the operation of nonprofit organizations offering financial assistance for prescription drugs in an effort to allow for the provision of medically necessary drugs to financially needy patients, and ensure the assistance is provided in a manner that does not conflict with the federal anti-kickback statute or other laws. As part of this effort, pharmaceutical manufacturers are prohibited from influencing enrollees’ drug choices through independent charity organizations; to help prevent this from happening, pharmaceutical manufacturers may not control which drugs an independent charities may offer to patients. The OIG is also concerned about the influence of nonprofit organizations providing financial assistance for prescription drugs on overall drug prices. OIG guidance states that although the agency recognizes that a patient prescribed an expensive drug may have a greater need for financial assistance than a patient prescribed a less expensive alternative, the OIG is concerned that limiting cost-sharing support from these organizations to expensive products may steer patients in a manner that is costly to federal health care programs and may even facilitate increases in drug prices. OIG guidance also specifies that the cost of the particular drug for which the patient is applying for assistance is not an appropriate stand-alone factor in determining individual financial need.
- Federal regulations on copayment adjustment programs. In July 2021, the Centers for Medicare & Medicaid Services’ (CMS) final rule on copayment adjustment programs deferred to states regarding their regulation for health plans sold on the exchanges and in nongrandfathered individual and group health plans sold off exchanges. Health plans and insurers were authorized to count payments associated with drug manufacturer financial assistance towards an enrollee’s cost-sharing limits but were not mandated to do so unless the state regulates them otherwise. The 2021 federal rule encouraged, but did not require, health plans and policies to disclose the use of copayment accumulator programs on websites, brochures, plan documents, and other materials. In September 2023, the U.S. District Court for the District of Columbia vacated, or set aside, this rule. An appeal from the federal government was withdrawn. The federal rule which allows insurers to stop applying the value of prescription drug coupons towards an enrollee’s maximum OOP costs in situations where a generic medication is available and medically appropriate, in order to encourage generic use and result in lower drug spending, applies in the marketplace today.
- Medicare. CMS allows for PAPs to provide assistance to Medicare Part D (prescription drug) enrollees; however, they must operate “outside the Part D benefit.” In other words, the payments made by a pharmaceutical patient assistance program do not count towards a Part D beneficiary’s true OOP cost. CMS uses the true OOP calculation to determine whether a beneficiary has reached the threshold for catastrophic coverage under the Part D benefit, after which Medicare covers all Part D drugs for the remainder of the calendar year.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP reviewed this bill and states the following in its analysis:
- Assumptions: PBMs typically only work with specialty pharmacies, which they either own or have exclusive contracts with, on implementation of copayment adjustment programs. CHBRP assumes that this bill would only impact specialty drugs, which are typically high-cost brand-name drugs. Specialty drugs come in various forms and may be billed under either the pharmacy benefit, medical benefit, or both. The timing of claims processing for specialty drugs varies significantly between those on the pharmacy versus medical benefit. Specialty drugs billed on the pharmacy benefit are processed in real time. In contrast, the billing system for medical benefit drugs is more complex, making it difficult to track claims and, therefore, track payments. In addition, claims for medical benefit drugs can take several weeks to process with third-party insurance. Because of this, it is difficult for PBMs to include medical benefit drugs in copayment adjustment programs. Thus, CHBRP assumes that specialty drugs administered in a medical setting are already compliant and this bill would only impact specialty drugs on the pharmacy benefit. CHBRP also considered how trends in biosimilars might impact assumptions for this bill. The interaction of biosimilar availability and adoption on this bill is potentially mixed. Considerations include the extent to which biosimilars are available from multiple manufacturers, the extent to which biosimilars impact drug prices (including rebates) as well as total member cost-sharing requirements, and the extent to which biosimilars are available and even preferred on formularies developed by PBMs. Biosimilars are a type of biologic medication and may be available at a lower cost than the original biologics (which include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins).
- Enrollees covered. CHBRP estimates the number of specialty prescriptions filled that have drug copay assistance (117,000) would not change due to this bill in the first year. This represents approximately 11,000 enrollees who will be impacted by this bill. Similarly, the average unit cost (for a 30-day fill) for specialty medications of $7,964 would not change from baseline to postmandate.
- Impact on expenditures. Postmandate, some enrollees would reach their OOPM earlier in the year as a result of this bill and would utilize services that they would not have used prior to enactment of the mandate; these additional services would be fully paid for by the health plans/insurers. Overall, this bill would increase total net annual expenditures for the first year by $24,714,000, or 0.02%, for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to a $52,745,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $28,031,000 decrease in enrollee expenses for covered and/or noncovered benefits. It should be noted that total net annual expenditures for the second year identifies an increase of $94,953,000.
Changes in premiums as a result of this bill would vary by market segment. Among DMHC-regulated plans, large-group premiums would increase by 0.03%, individual market premiums would increase by 0.03%, and CalPERS would increase by 0.01%. However, DMHC-regulated small-group premiums would increase by 0.12%. In the CDI-regulated market, the large-group market would face the smallest increase (0.12%), while individual (0.16%) and small group (0.17%) would have the highest increase across all markets.
CHBRP estimates this bill would result in enrollees in non-CalPERS commercial plans in all markets to pay less in OOP expenses. On average, DMHC-regulated large-group enrollees would experience a $0.10 reduction in enrollee expenses on the low end, with small-group DMHC-regulated enrollees experiencing a $0.48 decrease in enrollee expenses on the high end. For CDI-regulated enrollees, those with small-group ($0.92 decrease) and individual market ($0.68 decrease) policies would see the largest reduction in OOP expenses, while enrollees in large-group policies would experience $0.48 in reduced enrollee expenses on average. Overall, enrollee expenses would decrease by $28,031,000 across all markets. Due to the decreases in cost sharing, measurable public health impacts at the population level may occur if it results in increased adherence to a prescription drug.- CalPERS. Postmandate, for enrollees associated with CalPERS in DMHC-regulated plans, premiums would increase by 0.01% ($0.0066 per member per month, $429,000 total increase in expenditures).
- Covered California. Postmandate, premiums for enrollees in individual plans purchased through Covered California would increase by less than 0.01% (approximately $180,000 increase in total expenditures).
- Number of Uninsured in California. CHBRP expects no measurable change in the number of uninsured persons due to the enactment of this bill.
- EHBs. This bill does not appear to exceed the EHB definition, as all health plans and insurance carriers in California are already required to cover outpatient prescription drugs.
- Long-term impacts. In the longer term, CHBRP anticipates that this bill would incentivize manufacturers to increase funding to drug copay assistance through nonprofit organizations. Manufacturers would stand to benefit from increased drug copay assistance because by removing barriers to patient access to high-cost medications, manufacturers may increase the overall demand for specialty medications. Health plans and insurers may respond by removing specific high-cost specialty drugs that have therapeutic equivalent drugs from their formulary. Off-formulary drugs are not considered covered benefits, and therefore this bill would not apply to these drugs.
- Cost impacts. One key aspect of this bill is the degree to which patients may be willing to switch to alternative therapies when presented with an opportunity to reduce OOP expenditures. Drug copay assistance may influence patient behavior, as patients with drug copay assistance may be less likely to search for lower-cost, alternative treatment options. Furthermore, these programs may even minimize or eliminate cost sharing for all other medical services throughout the year if the OOPM is reached. The presence of these programs may have the long-term potential to encourage patients to continue a specific therapy even as less costly, equivalent therapies become available. Therefore, these programs may have the potential to increase overall costs for drugs over time. Another key consideration of this bill is the degree to which the mandate impacts patients with chronic disease versus terminal diseases. Due to the ongoing nature of treatments for chronic disease, the potential for higher utilization is greater for medications for chronic conditions than those for terminal diseases. CHBRP also notes that this bill may address inequalities because of the current consequences of cost sharing on low-income patients. At baseline, some patients may face financial hardships in order to receive needed treatments or even postpone treatment if nonprofit organizations have insufficient drug copay assistance to meet patient demand. Assuming this bill leads to an influx of additional financial contributions from pharmaceutical manufacturers and other organizations to copay assistance programs, the mandate may benefit those who would otherwise suffer financial hardship and may reduce health care disparities amongst lower income populations with commercial insurance. In addition, postmandate, some patients may no longer be compelled to pay up front for their prescriptions, as this bill eliminates the requirement to cover the deductible and OOPM for these patients, through drug copay assistance and a card processed by the PBM at the point of sale. This would benefit those who would otherwise suffer financial hardship, and may reduce health care disparities amongst lower-income populations with commercial insurance. In Year 2 (2026), CHBRP assumes that this factor would lead to increased utilization. It stands to reason that in the long run, this bill may improve the health status of patients who would not have otherwise received treatment.
- Other states. Massachusetts has also banned the use of discounts or other reductions for prescription drugs when a generic equivalent is available. Twenty states, including Arizona, Arkansas, Colorado, Connecticut, Delaware, Georgia, Illinois, Kentucky, Louisiana, Maine, New Mexico, New York, North Carolina, Oklahoma, Tennessee, Texas, Vermont, Virginia, Washington, and West Virginia, and the District of Columbia and Puerto Rico have enacted legislation banning copayment adjustment programs.
- Copay accumulator programs. Copayment adjustment programs are a type of pharmacy benefit design that offset the impacts of certain pharmaceutical financial assistance; they operate by prohibiting the contributions made by a third party from counting towards the enrollee’s OOPM. They may be designed to target specific drugs. Copayment adjustment programs are used to encourage the use of lower-cost prescription drugs, drive down drug prices, and reintroduce price sensitivity to enrollees who use financial assistance for OOP costs. There are two types of copayment adjustment programs: copay accumulator programs and copay maximizer combination programs.
- SUPPORT. The ALS Association, California Rheumatology Alliance, Cystic Fibrosis Research Institute, Hemophilia Council of California and Sickle Cell Disease Foundation (cosponsors) write that many Californians with chronic and terminal conditions rely on PAPs to afford their vital medications when there is no generic equivalent available to help them manage their complex or serious conditions and avoid costly health complications. Copay assistance provided from third-party sources for specific medications should not be confused with discounts, product vouchers or coupons that are available for general use and yield a percentage-based discount off the list price of a prescription drug. Unfortunately, nearly half of California-regulated commercial health plans and PBMs have copay accumulator policies, which are often obscurely stated in patients’ annual health plan benefit summaries, to prevent copay assistance from counting towards patients’ annual deductibles and maximum OOP cost-sharing. Moreover, health plans and PBMs are increasingly moving therapies covered through the pharmacy benefit to the medical benefit, which typically has a much higher copay and thus further increases the financial burden on patients who depend on such therapies. According to the co-sponsors, commercial health plans and PBMs that utilize copay accumulators are turning the financial copay assistance for medications intended to help patients in need into a financial windfall for themselves since they collect the third-party source payments made on patients’ behalf while also requiring these patients to pay their full annual OOP cost-share obligations, thereby double dipping. The adverse effect of copay accumulators is to nullify the financial relief that eligible patients would normally receive from participating in PAPs, putting these patients in greater harm when they discover that they can no longer afford their vital medications and raising overall health care costs due to unnecessary complications. This is also a health equity issue since copay accumulators have a disproportionate impact on the most vulnerable patients, including the underinsured and individuals with chronic or terminal conditions who often rely on multiple treatments to manage their illness and who have a higher OOP health care spend year-after-year than healthier patients. The co-sponsors conclude that this bill will ensure that patients who rely on costly treatments no longer must choose between filling their prescriptions or paying for other necessities.
- OPPOSITION. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans (collectively “opposition”) write that everyone should be able to get the medications they need at a cost they can afford. But drug prices continue to rise with no end in sight, and hardworking families feel the consequences every day. Prescription drug costs now represent over 22 cents out of every dollar of premium spent on health care. Drug manufacturers acknowledge their drugs are unaffordable for patients, but rather than choose to lower their prices for everyone, they point to their PAPs which offer copay coupons. Coupons are offered only to a narrow set of patients, for a narrow selection of drugs, and often only for a limited time. Once the patient hits their deductible, drugmakers discontinue the patient’s coupons. According to the opposition, this scheme allows drugmakers to keep their underlying prices hidden from patients, while keeping their costs extremely high for employers and consumers who end up paying much more in premiums and cost-sharing. The federal government considers copay coupons illegal kickbacks in federal health care programs like Medicare and Medicaid because these coupons induce a patient to use a specific drug. To counter the market manipulation from coupons, health plans and insurers have worked together with employers to develop programs to hold drug companies accountable, to shed light on these pricing schemes, and keep costs low for Californians. Such programs help restore the balance in the system by allowing patients to use manufacturer coupons to save money at the pharmacy counter, but does not count the amount the drug manufacturer has paid for the drug (through the coupon) towards the patient’s deductible or OOPM. Legislation like this bill that bans these programs by requiring health plans and insurers to count third-party payments towards an enrollee’s cost sharing obligations will eliminate incentives for drug companies to lower prices. The opposition concludes that as a result, drug companies will make more money while California families and businesses continue to foot the bill through higher premiums, higher OOP expenses, and higher federal insurance subsidies.
- RELATED LEGISLATION. SB 966 (Wiener) requires a PBM, as defined by the bill, to apply for and obtain a license from the Board of Pharmacy (board) to operate as a PBM. Requires a PBM, on or before April 1, 2027, and annually thereafter, to file with the board a report containing specified information. Prohibits the report from disclosure to the public. Requires the board, on or before August 1, 2027, and annually thereafter, to submit a report to the Legislature based on the reports submitted by licensees, and requires the board to post the report on the board’s internet website. Imposes specified duties, including prohibiting a PBM from deriving income from PBM services, except as specified. SB 966 was recently amended in Senate Business, Professions and Economic Development Committee and is pending in Senate Health Committee.
- PREVIOUS LEGISLATION.
- AB 874 (Weber) of 2023 was similar to this bill but was never heard in Assembly Health Committee.
- SB 873 (Bradford) of 2023 would have required an enrollee’s or insured’s defined cost sharing for each prescription drug to be calculated at the point of sale based on a price that is reduced by an amount equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. Would have required DMHC and CDI to submit an annual report on the impact of these provisions to the appropriate policy committees of the Legislature, as specified. SB 873 was held on suspense in the Assembly Appropriations Committee.
- AB 948 (Berman), Chapter, Statutes of 2023, makes permanent existing law provisions that prohibit the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription from exceeding $250 for a supply of up to 30 days or $500 for bronze products, except as specified.
- AB 933 (Daly) of 2021 is substantially similar to SB 873 and was held on suspense in the Assembly Appropriations Committee.
- AB 290 (Wood), Chapter 862, Statutes of 2019, requires a health plan or an insurer that provides a policy of health insurance to accept payments from specified third-party entities, including an Indian tribe or a local, state, or federal government program. Requires a financially interested entity, as defined, other than those entities, that is making a third-party premium payment, to provide that assistance and to perform other related duties, including disclosing to the plan or the insurer the name of the enrollee or insured, as applicable, for each plan or policy on whose behalf a third-party premium payment will be made. Requires each plan or insurer to provide to the appropriate department information regarding premium payments by financially interested entities and reimbursement for services to providers, and would set forth standards governing the reimbursement of financially interested providers, including, but not limited to, chronic dialysis clinics, that meet certain criteria. Requires reimbursement to contracted providers to be the higher of the Medicare reimbursement rate or the rate determined pursuant to an independent dispute resolution process, as prescribed.
- AB 315 (Wood), Chapter 905, Statutes of 2018, requires health plans that contract with PBMs to register with the DMHC.
- AB 265 (Wood), Chapter 611, Statutes of 2017, prohibits prescription drug manufacturers from offering discounts or other reduction in an individual's OOP expenses associated with his or her insurance coverage, if a lower cost therapeutically equivalent generic drug is available. Specifies a number of exceptions that allow discounts even if a lower cost therapeutically equivalent generic drug is available.
- SB 17 (Hernandez), Chapter 603, Statutes of 2017, requires health plans and insurers that report rate information through the existing large and small group rate review process to also report specified information related to prescription drug pricing to DMHC and CDI. Requires DMHC and CDI to compile specified information into a consumer-friendly report that demonstrates the overall impact of drug costs on health care premiums. Requires drug manufacturers to notify specified purchasers, in writing at least 90 days prior to the planned effective date, if it is increasing the wholesale acquisition cost of a prescription drug by specified amounts. Requires drug manufacturers to notify the the Department of Health Care Access and Information (HCAI) three days after FDA approval when introducing a new drug to market, as specified. Requires drug manufacturers to provide specified information to HCAI related to the drug’s price.
- AMENDMENTS. The Committee is recommending the following amendments to address some of the potential unintended consequences raised by the CHBRP analysis:
- Add a sunset and authorize the regulators to conduct an analysis of this bill and its impact to consumers and whether or not the Legislature should eliminate the sunset;
- Update SB 17 reporting to include PAPs;
- Require notices to enrollees on the availability of the PAP during the contract period; and,
- Limit this bill to prescription drugs.
- COMMENTS.
- Specialty Drugs. As part of this analysis, CHBRP assumed that compliance with this mandate will impact only specialty medications, as PBMs rely on specialty pharmacies to handle pricing adjustments at point-of-sale to administer these programs. As the recent SB 17 report pointed out, the cost of specialty drugs continues to be a driver of overall health care costs. In the second year of implementation, total net annual expenditures is $94,953,000. As drafted, there is nothing in this bill that guarantees or controls how much manufacturers could increase their prices. To address concerns that PAPs may facilitate increased in drug prices, should this bill be amended such that PAPs must be applied towards the enrollee’s OOPM only if there is no generic equivalent and consistent with AB 265 which prohibits prescription drug coupons when there is a generic available?
- Prescription Drug Coupons. This bill, as introduced, excluded general manufacturer coupons. Recent amendments now specify, “third-party patient assistance program does not include discounts, product vouchers, or coupons that provide a percentage-based discount off the list price of a prescription drug.” Since this language is different from CHBRP’s current analysis, the Committee may wish to request an updated analysis to reflect the current language of this bill.
REGISTERED SUPPORT / OPPOSITION:
Support
ALS Association (cosponsor)
California Rheumatology Alliance (cosponsor)
Cystic Fibrosis Research Institute (cosponsor)
Hemophilia Council of California (cosponsor)
Sickle Cell Disease Foundation (co-sponsor)
AIDS Healthcare Foundation
Aim At Melanoma Foundation
Aimed Alliance
Alliance for Gout Awareness
Alliance for Patient Access
American Cancer Society Cancer Action Network INC.
American Diabetes Association
Arthritis Foundation
Association for Clinical Oncology
Association of Northern California Oncologists
Association of Women in Rheumatology (AWIR)
California Academy of Physician Assistants
California Black Health Network
California Chapter American College of Cardiology
California Chronic Care Coalition
California Life Sciences
California Medical Association
California Pharmacists Association
California Retired Teachers Association
California Society of Dermatology & Dermatologic Surgery
California Society of Plastic Surgeons
California Urological Association
Cancer Support Community San Francisco Bay Area
Center for Inherited Blood Disorders
Central California Hemophilia Foundation
Children's Hospital Los Angeles
Children's Specialty Care Coalition
Chronic Care Policy Alliance
Chronic Disease Coalition
Community Oncology Alliance (COA)
Crohns and Colitis Foundation
Cystic Fibrosis Foundation
Everylife Foundation for Rare Diseases
Global Healthy Living Foundation
Head
Hemophilia Federation of America
Hemophilia Foundation of Northern California
Hemophilia Foundation of Southern California
HIV + Hepatitis Policy Institute
ICAN, International Cancer Advocacy Network
Infusion Access Foundation (IAF)
International Foundation for Autoimmune and Inflammatory Arthritis
Looms for Lupus
Lung Cancer Foundation of America
Lungevity Foundation
Lupus and Allied Diseases Association, INC.
Medical Oncology Association of Southern California
Movement Disorders Policy Coalition
National Bleeding Disorders Foundation
National Health Law Program
National Infusion Center Association (NICA)
National Multiple Sclerosis Society, Ms-can
National Psoriasis Foundation
Oncology Nursing Society
Osteopathic Physicians and Surgeons of California
Rady Children's Hospital San Diego
Spondylitis Assocation of America
Support Fibromyalgia Network
The AIDS Institute
The Defeating Epilepsy Foundation
The Hemophilia Association of San Diego County
UCSF Adult Hemophilia Treatment Center
Vision Health Advocacy Coalition
We Win Foundation
Opposition
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
Pharmaceutical Care Management Association
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Standing Committee on Health
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):